Press coverage about Cambrex (NYSE:CBM) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cambrex earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.0466297306085 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Reviewing Cambrex (CBM) & Its Rivals (americanbankingnews.com)
- Comparing Cambrex (CBM) and Innocoll (INNL) (americanbankingnews.com)
- Comparing Cambrex (CBM) & Its Peers (americanbankingnews.com)
- Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : December 11, 2017 (finance.yahoo.com)
CBM has been the subject of several research reports. ValuEngine raised shares of Cambrex from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. Craig Hallum reaffirmed a “buy” rating and set a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Finally, BidaskClub cut shares of Cambrex from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $62.33.
Cambrex (NYSE:CBM) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The business had revenue of $112.60 million during the quarter, compared to analysts’ expectations of $108.44 million. During the same quarter in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. analysts anticipate that Cambrex will post 2.97 earnings per share for the current year.
In other news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.48% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cambrex (CBM) Share Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cambrex-cbm-share-price.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
What are top analysts saying about Cambrex? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cambrex and related companies.